|
1
|
Metz-Boutigue MH, Jollès J, Mazurier J,
Schoentgen F, Legrand D, Spik G, et al: Human lactotransferrin:
amino acid sequence and structural comparisons with other
transferrins. Eur J Biochem. 145:659–676. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanyshkova TG, Buneva VN and Nevinsky GA:
Lactoferrin and its biological functions. Biochemistry (Mosc).
66:1–7. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nuijens JH, van Berkel PH and Schanbacher
FL: Structure and biological actions of lactoferrin. J Mammary
Gland Biol Neoplasia. 1:285–295. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levay PF and Viljoen M: Lactoferrin: a
general review. Haematologica. 80:252–267. 1995.PubMed/NCBI
|
|
5
|
Vorland LH: Lactoferrin: a multifunctional
glycoprotein. APMIS. 107:971–981. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu T, Zhang YZ and Wu XF: High level
expression of functionally active human lactoferrin in silkworm
larvae. J Biotechnol. 118:246–256. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van der Strate BW, Beljaars L, Molema G,
Harmsen MC and Meijer DK: Antiviral activities of lactoferrin.
Antiviral Res. 52:225–239. 2001.
|
|
8
|
Cumberbatch M, Dearman RJ, Uribe-Luna S,
Headon DR, Ward PP, Conneely OM and Kimber I: Regulation of
epidermal Langerhans cell migration by lactoferrin. Immunology.
100:21–28. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoo YC, Watanabe S, Watanabe R, Hata K,
Shimazaki K and Azuma I: Bovine lactoferrin and lactoferricin, a
peptide derived from bovine lactoferrin, inhibit tumor metastasis
in mice. Jpn J Cancer Res. 88:184–190. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cho E, Smith-Warner SA, Spiegelman D,
Beeson WL, van den Brandt PA, Colditz GA, et al: Dairy foods,
calcium, and colorectal cancer: a pooled analysis of 10 cohort
studies. J Natl Cancer Inst. 96:1015–1022. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsuda H, Sekine K, Nakamura J, Ushida Y,
Kuhara T, Takasuka N, et al: Inhibition of azoxymethane initiated
colon tumor and aberrant crypt foci development by bovine
lactoferrin administration in F344 rats. Adv Exp Med Biol.
443:273–284. 1998. View Article : Google Scholar
|
|
12
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rees S, Coote J, Stables J, Goodson S,
Harris S and Lee MG: Bicistronic vector for the creation of stable
mammalian cell lines that predisposes all antibiotic-resistant
cells to express recombinant protein. Biotechniques. 20:102–104.
106108–110. 1996.
|
|
14
|
Cheng M, Zhang J, Jiang W, Chen Y and Tian
Z: Natural killer cell lines in tumor immunotherapy. Front Med.
6:56–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kiessling R, Klein E and Wigzell H:
‘Natural’ killer cells in the mouse. I Cytotoxic cells with
specificity for mouse Moloney leukemia cells Specificity and
distribution according to genotype. Eur J Immunol. 5:112–117.
1975.
|
|
16
|
Glässner A, Eisenhardt M, Krämer B, Körner
C, Coenen M, Sauerbruch T, et al: NK cells from HCV-infected
patients effectively induce apoptosis of activated primary human
hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent
manner. Lab Invest. 92:967–977. 2012.
|
|
17
|
Kuss I, Hathaway B, Ferris RL, Gooding W
and Whiteside TL: Decreased absolute counts of T lymphocyte subsets
and their relation to disease in squamous cell carcinoma of the
head and neck. Clin Cancer Res. 10:3755–3762. 2004. View Article : Google Scholar
|
|
18
|
Tembhre MK and Sharma VK: T-helper and
regulatory T-cell cytokines in the peripheral blood of patients
with active alopecia areata. Br J Dermatol. 169:543–548. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tie J and Desai J: Antiangiogenic
therapies targeting the vascular endothelial growth factor
signaling system. Crit Rev Oncog. 17:51–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masuda C, Wanibuchi H, Sekine K, Yano Y,
Otani S, Kishimoto T, et al: Chemopreventive effects of bovine
lactoferrin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat
bladder carcinogenesis. Jpn J Cancer Res. 91:582–588. 2000.
View Article : Google Scholar
|
|
21
|
Bezault J, Bhimani R, Wiprovnick J and
Furmanski P: Human lactoferrin inhibits growth of solid tumors and
development of experimental metastases in mice. Cancer Res.
54:2310–2012. 1994.PubMed/NCBI
|
|
22
|
Iigo M, Kuhara T, Ushida Y, Sekine K,
Moore MA and Tsuda H: Inhibitory effects of bovine lactoferrin on
colon carcinoma 26 lung metastasis in mice. Clin Exp Metastasis.
17:35–40. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ushida Y, Sekine K, Kuhara T, Takasuka N,
Iigo M and Tsuda H: Inhibitory effects of bovine lactoferrin on
intestinal polyposis in the Apc(Min) mouse. Cancer Lett.
134:141–145. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ushida Y, Sekine K, Kuhara T, Takasuka N,
Iigo M, Maeda M and Tsuda H: Possible chemopreventive effects of
bovine lactoferrin on esophagus and lung carcinogenesis in the rat.
Jpn J Cancer Res. 90:262–267. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tanaka T, Kawabata K, Kohno H, Honjo S,
Murakami M, Ota T and Tsuda H: Chemopreventive effect of bovine
lactoferrin on 4-nitroquinoline 1-oxide-induced tongue
carcinogenesis in male F344 rats. Jpn J Cancer Res. 91:25–33. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li WY, Li QW, Han ZS, Jiang ZL, Yang H, Li
J and Zhang XB: Growth suppression effects of recombinant
adenovirus expressing human lactoferrin on cervical cancer in vitro
and in vivo. Cancer Biother Radiopharm. 26:477–483. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arina A, Murillo O, Dubrot J, Azpilikueta
A, Alfaro C, Pérez-Gracia JL, et al: Cellular liaisons of natural
killer lymphocytes in immunology and immunotherapy of cancer.
Expert Opin Biol Ther. 7:599–615. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trapani JA and Smyth MJ: Functional
significance of the perforin/granzyme cell death pathway. Nat Rev
Immunol. 2:735–747. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kannan Y, Yu J, Raices RM, Seshadri S, Wei
M, Caligiuri MA and Wewers MD: IκBζ augments IL-12- and
IL-18-mediated IFN-γ production in human NK cells. Blood.
117:2855–2863. 2011.
|
|
30
|
Raja A: Immunology of tuberculosis. Indian
J Med Res. 120:213–232. 2004.
|
|
31
|
Van Elssen CH, Vanderlocht J, Oth T,
Senden-Gijsbers BL, Germeraad WT and Bos GM:
Inflammation-restraining effects of prostaglandin E2 on natural
killer-dendritic cell (NK-DC) interaction are imprinted during DC
maturation. Blood. 118:2473–2482. 2011.
|
|
32
|
Reefman E, Kay JG, Wood SM, Offenhäuser C,
Brown DL, Roy S, et al: Cytokine secretion is distinct from
secretion of cytotoxic granules in NK cells. J Immunol.
184:4852–4862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Smyth MJ, Hayakawa Y, Takeda K and Yagita
H: New aspects of natural-killer-cell surveillance and therapy of
cancer. Nat Rev Cancer. 2:850–861. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shanker A, Buferne M and Schmitt-Verhulst
AM: Cooperative action of CD8 T lymphocytes and natural killer
cells controls tumour growth under conditions of restricted T-cell
receptor diversity. Immunology. 129:41–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jenq RR, Curran MA, Goldberg GL, Liu C,
Allison JP and van den Brink MR: Repertoire enhancement with
adoptively transferred female lymphocytes controls the growth of
pre-implanted murine prostate cancer. PLoS One. 7:e352222012.
View Article : Google Scholar
|
|
36
|
Banchereau J and Steinman RM: Dendritic
cells and the control of immunity. Nature. 392:245–252. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blanchard DK, Wei S, Duan C, Pericle F,
Diaz JI and Djeu JY: Role of extracellular adenosine triphosphate
in the cytotoxic T-lymphocyte-mediated lysis of antigen presenting
cells. Blood. 85:3173–3182. 1995.PubMed/NCBI
|
|
38
|
Hamza T, Barnett JB and Li B: Interleukin
12 a key immunoregulatory cytokine in infection applications. Int J
Mol Sci. 11:789–806. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Seger J, Zorzella-Pezavento SF, Pelizon
AC, Martins DR, Domingues A and Sartori A: Decreased production of
TNF-alpha by lymph node cells indicates experimental autoimmune
encephalomyelitis remission in Lewis rats. Mem Inst Oswaldo Cruz.
105:263–268. 2010. View Article : Google Scholar
|
|
40
|
Hartenstein B, Teurich S, Hess J, Schenkel
J, Schorpp-Kistner M and Angel P: Th2 cell-specific cytokine
expression and allergen-induced airway inflammation depend on JunB.
EMBO J. 21:6321–6329. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Metelitsa LS, Naidenko OV, Kant A, Wu HW,
Loza MJ, Perussia B, et al: Human NKT cells mediate antitumor
cytotoxicity directly by recognizing target cell CD1d with bound
ligand or indirectly by producing IL-2 to activate NK cells. J
Immunol. 167:3114–3122. 2001. View Article : Google Scholar
|
|
42
|
Xu Z, Hurchla MA, Deng H, Uluçkan O, Bu F,
Berdy A, et al: Interferon-gamma targets cancer cells and
osteoclasts to prevent tumor-associated bone loss and bone
metastases. J Biol Chem. 284:4658–4666. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Koch F, Stanzl U, Jennewein P, Janke K,
Heufler C, Kämpgen E, et al: High level IL-12 production by murine
dendritic cells: upregulation via MHC class II and CD40 molecules
and downregulation by IL-4 and IL-10. J Exp Med. 184:741–746.
1996.PubMed/NCBI
|
|
44
|
Flesch IE, Hess JH, Oswald IP and Kaufmann
SH: Growth inhibition of Mycobacterium bovis by IFN-gamma
stimulated macrophages: regulation by endogenous tumor necrosis
factor-alpha and by IL-10. Int Immunol. 6:693–700. 1994.
|
|
45
|
Alcami A and Koszinowski UH: Viral
mechanisms of immune evasion. Mol Med Today. 6:365–372. 2000.
View Article : Google Scholar
|
|
46
|
Hayakawa Y, Takeda K, Yagita H, Smyth MJ,
Van Kaer L, Okumura K and Saiki I: IFN-gamma-mediated inhibition of
tumor angiogenesis by natural killer T-cell ligand,
alpha-galactosylceramide. Blood. 100:1728–1733. 2002.PubMed/NCBI
|
|
47
|
Davis-Smyth T, Chen H, Park J, Presta LG
and Ferrara N: The second immunoglobulin-like domain of the VEGF
tyrosine kinase receptor Flt-1 determines ligand binding and may
initiate a signal transduction cascade. EMBO J. 15:4919–4927.
1996.
|
|
48
|
Carmeliet P: Angiogenesis in health and
disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sukhramani PS and Suthar MP: VEGF
inhibitors for cancer therapy. IJPSDR. 2:1–11. 2010.
|
